Publikation

Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus.

Wissenschaftlicher Artikel/Review - 02.02.2022

Bereiche
PubMed
DOI
Kontakt

Zitation
Frei N, Stachler M. Today's Mistakes and Tomorrow's Wisdom in Development and Use of Biomarkers for Barrett's Esophagus. Visc Med 2022; 38:173-181.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Visc Med 2022; 38
Veröffentlichungsdatum
02.02.2022
ISSN (Druck)
2297-4725
Seiten
173-181
Kurzbeschreibung/Zielsetzung

A histological diagnosis of dysplasia is our current best predictor of progression in Barrett's esophagus (BE), the precursor of esophageal adenocarcinoma (EAC). Despite periodic endoscopic surveillance and assessment of dysplastic changes, we fail to identify the majority of those who progress before the development of EAC, whereas the majority of patients undergo endoscopy without showing progression.